HACKENSACK, N.J., Aug. 21, 2015 /PRNewswire/ -- Champions
Oncology, Inc. (CSBR), engaged in the development of advanced
technology solutions and services to personalize the development
and use of oncology drugs, announced that it has commenced trading
on the NASDAQ Capital Market effective today.
Joel Ackerman, Chief Executive
Officer commented, "Uplisting to a national exchange like NASDAQ
has been a goal towards which we have been working for years.
We are pleased to reach this important milestone in the Company's
history. We expect this will provide us with increased
visibility in the capital markets and access to a broader investor
base, which ultimately should provide us with better access to
capital."
Champions' common stock began trading under the same symbol
(CSBR) at the opening of trading on August
21, 2015.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Champions
TumorGraft® technology platform is a novel approach to
personalizing cancer care based upon the implantation of primary
human tumors in immune deficient mice followed by propagation of
the resulting engraftments in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. Champions TumorGraft
models are procured through agreements with a number of
institutions in the U.S. and overseas as well as through Champions'
Personalized Oncology Solutions business. For more information,
please visit www.championsoncology.com.
Forward Looking Statement
This press release may contain "forward-looking statements"
(within the meaning of the Private Securities Litigation Act of
1995) that inherently involve risk and uncertainties.
Champions Oncology generally uses words such as "believe," "may,"
"could," "will," "intend," "expect," "anticipate," "plan," and
similar expressions to identify forward-looking statements.
One should not place undue reliance on these forward-looking
statements. The Company's actual results could differ
materially from those anticipated in the forward-looking statements
for many unforeseen factors. See Champions Oncology's Form
10-K for the fiscal year ended April 30,
2015 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Oncology's future results, levels of activity,
performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions Oncology's
expectations, except as required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-announces-uplisting-to-nasdaq-300131758.html
SOURCE Champions Oncology, Inc.